Digestive Diseases and Sciences

, Volume 60, Issue 8, pp 2488–2494 | Cite as

Vitamin D Deficiency Adds an Element of Risk to Insulin Resistance in Colorectal Neoplasms

  • Myong Ki Baeg
  • Myung-Gyu Choi
  • Sun-Hye Ko
  • Bo-Geun Park
  • Kyung-Do Han
  • Jae Myung Park
  • Bo-In Lee
  • In-Seok Lee
  • Sang-Woo Kim
Original Article
First Online:
Received:
Accepted:
  • 221 Downloads

Abstract

Background

Both insulin resistance (IR) and vitamin D deficiency (VitDdef) have been suggested as risk factors for colorectal neoplasms (CRNs). However, the associations between the two with regard to CRNs are unclear.

Aims

To determine whether IR is a risk factor for CRNs and whether VitDdef confers an additive risk of CRNs.

Methods

Colonoscopy-naïve asymptomatic women undergoing a routine health screening program were analyzed. IR was defined as homeostatic model assessment of IR >3 and VitDdef set as <20 ng/mL. Multivariable logistic regression was performed between women with and without CRNs, matched for age and body mass index, to investigate associations with CRNs in IR, VitDdef, and VitDdef combined with IR.

Results

We analyzed 216 women with CRNs and 216 without CRNs. A significant association was found between IR and CRNs (OR 1.838, 95 % CI 1.029–3.285, P = 0.040) but not with VitDdef. IR conferred a higher risk in advanced CRNs (OR 3.244, 95 % CI 1.588–6.631, P = 0.001) than CRNs. When VitDdef was combined with IR, risks of both CRNs and advanced CRNs increased (OR 2.131, 95 % CI 1.077–4.216, P = 0.030 and OR 4.438, 95 % CI 2.058–9.571, P < 0.001, respectively).

Conclusions

IR increases the risk of CRNs, and a combination of IR and VitDdef further increases this risk. As both VitDdef and IR are modifiable risk factors, such associations may have important clinical implications in the prevention of CRNs.

Keywords

Colorectal neoplasm Colorectal adenoma Colorectal carcinoma Insulin resistance Vitamin D deficiency 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

This research was supported by program of Global Research and Development Center through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT, and Future Planning (NRF-2011-0031644).

Conflict of interest

None.

References

  1. 1.
    Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106:1911–1921; quiz 1922.Google Scholar
  2. 2.
    Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, Paul O. Dietary vitamin D and calcium and risk of colorectal cancer: a 19-year prospective study in men. Lancet. 1985;1:307–309.PubMedCrossRefGoogle Scholar
  3. 3.
    Bardou M, Barkun AN, Martel M. Obesity and colorectal cancer. Gut. 2013;62:933–947.PubMedCrossRefGoogle Scholar
  4. 4.
    Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer. J Natl Cancer Inst. 2002;94:972–980.PubMedCrossRefGoogle Scholar
  5. 5.
    Sax AT, Jenkins DG, Devin JL, Hughes GI, Bolam KA, Skinner TL. The insulin-like growth factor axis: a biological mechanism linking physical activity to colorectal cancer survival. Cancer Epidemiol. 2014;38:455–459.PubMedCrossRefGoogle Scholar
  6. 6.
    Schoen RE, Weissfeld JL, Kuller LH, et al. Insulin-like growth factor-I and insulin are associated with the presence and advancement of adenomatous polyps. Gastroenterology. 2005;129:464–475.PubMedCrossRefGoogle Scholar
  7. 7.
    Rampal S, Yang MH, Sung J, et al. Association between markers of glucose metabolism and risk of colorectal adenoma. Gastroenterology. 2014;147:78–87 e73.Google Scholar
  8. 8.
    Tsilidis KK, Brancati FL, Pollak MN, et al. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control. 2010;21:1–10.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol. 2011;29:3775–3782.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee JE, Li H, Chan AT, et al. Circulating levels of vitamin D and colon and rectal cancer: the Physicians’ Health Study and a meta-analysis of prospective studies. Cancer Prev Res (Phila). 2011;4:735–743.CrossRefGoogle Scholar
  11. 11.
    Giovannucci E. The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control. 2005;16:83–95.PubMedCrossRefGoogle Scholar
  12. 12.
    Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer. 2014;14:342–357.PubMedCrossRefGoogle Scholar
  13. 13.
    Hong SN, Kim JH, Choe WH, et al. Circulating vitamin D and colorectal adenoma in asymptomatic average-risk individuals who underwent first screening colonoscopy: a case–control study. Dig Dis Sci. 2012;57:753–763.PubMedCrossRefGoogle Scholar
  14. 14.
    Peters U, McGlynn KA, Chatterjee N, et al. Vitamin D, calcium, and vitamin D receptor polymorphism in colorectal adenomas. Cancer Epidemiol Biomark Prev. 2001;10:1267–1274.Google Scholar
  15. 15.
    Fedirko V, Bostick RM, Goodman M, Flanders WD, Gross MD. Blood 25-hydroxyvitamin D3 concentrations and incident sporadic colorectal adenoma risk: a pooled case–control study. Am J Epidemiol. 2010;172:489–500.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Platz EA, Hankinson SE, Hollis BW, et al. Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and adenomatous polyps of the distal colorectum. Cancer Epidemiol Biomark Prev. 2000;9:1059–1065.Google Scholar
  17. 17.
    Jacobs ET, Alberts DS, Benuzillo J, Hollis BW, Thompson PA, Martinez ME. Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. J Steroid Biochem Mol Biol. 2007;103:752–756.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Zheng XE, Lipka S, Li T, et al. The relationship of vitamin D status, smoking, and colorectal adenoma: a retrospective study in an ethnically diverse community. J Steroid Biochem Mol Biol. 2013;136:280–283.PubMedCrossRefGoogle Scholar
  19. 19.
    Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care. 2005;28:1228–1230.PubMedCrossRefGoogle Scholar
  20. 20.
    Amirbaigloo A, Hosseinpanah F, Sarvghadi F, Tohidi M, Eskandary PS, Azizi F. Absence of association between vitamin D deficiency and incident metabolic syndrome: tehran lipid and glucose study. Metab Syndr Relat Disord. 2013;11:236–242.PubMedCrossRefGoogle Scholar
  21. 21.
    Al-Shoumer KA, Al-Asoosi AA, Ali AH, Nair VS. Does insulin resistance in type 2 diabetes alter vitamin D status? Prim Care Diabetes. 2013;7:283–287.PubMedCrossRefGoogle Scholar
  22. 22.
    Tuohimaa P, Tenkanen L, Syvala H, et al. Interaction of factors related to the metabolic syndrome and vitamin D on risk of prostate cancer. Cancer Epidemiol Biomark Prev. 2007;16:302–307.CrossRefGoogle Scholar
  23. 23.
    Murtaugh MA, Sweeney C, Ma KN, et al. Vitamin D receptor gene polymorphisms, dietary promotion of insulin resistance, and colon and rectal cancer. Nutr Cancer. 2006;55:35–43.PubMedCrossRefGoogle Scholar
  24. 24.
    Wu K, Feskanich D, Fuchs CS, Willett WC, Hollis BW, Giovannucci EL. A nested case control study of plasma 25-hydroxyvitamin D concentrations and risk of colorectal cancer. J Natl Cancer Inst. 2007;99:1120–1129.PubMedCrossRefGoogle Scholar
  25. 25.
    Choi EY. 25(OH)D status and demographic and lifestyle determinants of 25(OH)D among Korean adults. Asia Pac J Clin Nutr. 2012;21:526–535.PubMedGoogle Scholar
  26. 26.
    Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640–1645.PubMedCrossRefGoogle Scholar
  27. 27.
    Lee S, Choi S, Kim HJ, et al. Cutoff values of surrogate measures of insulin resistance for metabolic syndrome in Korean non-diabetic adults. J Korean Med Sci. 2006;21:695–700.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Rosen CJ, Gallagher JC. The 2011 IOM report on vitamin D and calcium requirements for north America: clinical implications for providers treating patients with low bone mineral density. J Clin Densitom. 2011;14:79–84.PubMedCrossRefGoogle Scholar
  29. 29.
    Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–857.PubMedCrossRefGoogle Scholar
  30. 30.
    Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57:1576–1585.PubMedCrossRefGoogle Scholar
  31. 31.
    Yamamoto S, Nakagawa T, Matsushita Y, et al. Visceral fat area and markers of insulin resistance in relation to colorectal neoplasia. Diabetes Care. 2010;33:184–189.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Peters U, Hayes RB, Chatterjee N, et al. Circulating vitamin D metabolites, polymorphism in vitamin D receptor, and colorectal adenoma risk. Cancer Epidemiol Biomark Prev. 2004;13:546–552.Google Scholar
  33. 33.
    Wei MY, Garland CF, Gorham ED, Mohr SB, Giovannucci E. Vitamin D and prevention of colorectal adenoma: a meta-analysis. Cancer Epidemiol Biomark Prev. 2008;17:2958–2969.CrossRefGoogle Scholar
  34. 34.
    Jacobs ET, Hibler EA, Lance P, Sardo CL, Jurutka PW. Association between circulating concentrations of 25(OH)D and colorectal adenoma: a pooled analysis. Int J Cancer. 2013;133:2980–2988.PubMedCentralPubMedGoogle Scholar
  35. 35.
    Seo JA, Eun CR, Cho H, et al. Low vitamin D status is associated with nonalcoholic fatty liver disease independent of visceral obesity in Korean adults. PLoS ONE. 2013;8:e75197.PubMedCentralPubMedCrossRefGoogle Scholar
  36. 36.
    Mitri J, Pittas AG. Vitamin D and diabetes. Endocrinol Metab Clin N Am. 2014;43:205–232.CrossRefGoogle Scholar
  37. 37.
    Gulseth HL, Gjelstad IM, Birkeland KI, Drevon CA. Vitamin D and the metabolic syndrome. Curr Vasc Pharmacol. 2013;11:968–984.PubMedCrossRefGoogle Scholar
  38. 38.
    Merrimen JL, Evans AJ, Srigley JR. Preneoplasia in the prostate gland with emphasis on high grade prostatic intraepithelial neoplasia. Pathology. 2013;45:251–263.PubMedCrossRefGoogle Scholar
  39. 39.
    Mitri J, Dawson-Hughes B, Hu FB, Pittas AG. Effects of vitamin D and calcium supplementation on pancreatic beta cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr. 2011;94:486–494.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol. 1998;20:157–162.PubMedCrossRefGoogle Scholar
  41. 41.
    Brosseau C, Pirianov G, Colston KW. Role of insulin-like growth factor binding protein-3 in 1, 25-dihydroxyvitamin-d 3-induced breast cancer cell apoptosis. Int J Cell Biol. 2013;2013:960378.PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    Oh YS, Kim EJ, Schaffer BS, et al. Synthetic low-calcaemic vitamin D(3) analogues inhibit secretion of insulin-like growth factor II and stimulate production of insulin-like growth factor-binding protein-6 in conjunction with growth suppression of HT-29 colon cancer cells. Mol Cell Endocrinol. 2001;183:141–149.PubMedCrossRefGoogle Scholar
  43. 43.
    Martin JL, Baxter RC. Signalling pathways of insulin-like growth factors (IGFs) and IGF binding protein-3. Growth Factors. 2011;29:235–244.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Myong Ki Baeg
    • 1
  • Myung-Gyu Choi
    • 1
  • Sun-Hye Ko
    • 2
  • Bo-Geun Park
    • 1
  • Kyung-Do Han
    • 3
  • Jae Myung Park
    • 1
  • Bo-In Lee
    • 1
  • In-Seok Lee
    • 1
  • Sang-Woo Kim
    • 1
  1. 1.Division of Gastroenterology, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  2. 2.Division of Endocrinology and Metabolism, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  3. 3.Department of Biostatistics, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea

Personalised recommendations